Metabolic characteristics in women with polycystic ovary syndrome by phenotypes based on various diagnostic criteria

Y. Sung; D. Kim; S. Baik; K. Won; H. Kim; J. Oh; H. Lee

The metabolic features of Polycystic ovary syndrome (PCOS) can vary based on the definition used. The aim of this study is to compare the metabolic characteristics of PCOS according to the phenotypes from various diagnostic criteria and help to establish a optimal diagnostic criteria.

Subjects with PCOS defined by the NIH criteria (n=494) and the Rotterdam criteria (n=568) and regular cycling non-hirsuite control women (n=1000) were recruited. All subjects underwent blood samples for fasting glucose, lipids, insulin and reproductive hormones and a transvaginal ultrasound.

Women with PCOS have significantly higher prevalence for abnormal glucose metabolism and metabolic syndrome (MetS) compared to control (4 vs 0% for diabetes 11 vs 3.4% for IFG/IGTand 19 vs 2.4% for MetS) and it is not different among PCOS women according to diagnostic criteria. Women with PCOS were divided into following four different phenotypes; i) oligomenorrhea(OM)/hyperandrogenism (HA)/PCO, ii) OM/ HA, iii) HA /PCO, and iv)OM/PCO. Women with PCOS by NIH criteria (OM/HA±PCO) have higher frequency of obesity, diabetes, IGT/IFG and metabolic syndrome compared to subjects with OM/PCO or HA/PCO (Table 1).

Regarding metabolic derangement, PCOS without HA may be different phenotype. Further studies will be required to observe the development of various disease in women with PCOS diagnosed by different criteria to establish a fine definition which can represent morbidity of disease.

Table 1 Metabolic characteristics according to various phenotypes of PCOS.
	OM/HA/PCO (n=346)	OM/HA (n=165)	HA/PCO (n=136)	OM/PCO (413)	Controls (n=962)
Age (year)	24±5^*,§	23±4^*,‡	25±4^†	24±4^*	26±4
BMI (kg/m²)	23.8±4.7^*,†,‡	23.4±4.5^*,†,‡	21.2±2.9	20.8±2.4	20.9±2.5
FPG (mg/dl)	87±13^†	86±18	85±8	84±7	85±6
PPG (mg/dl)	111±36^*,†,‡	109±41^*,†,‡	98±17	96±20	95±18
TC (mg/dl)	183±31^*,†	184±333^*,†	178±28	174±28	174±28
TG (mg/dl)	100±64^*,†,‡	93±53^*,†	78±36	72±36	73±34
HDL-C (mg/dl)	50±13	50±15	50±9	53±11	50±10
LDL-C (mg/dl)	113±28^†	116±28	112±26	107±23	109±24
FPI (IU/l)	7.8±7.2^*,†	5.9±5.7	4.4±3.6	4.4±3.6	3.8±4.7
PPI (IU/l)	51.6±46.1^*,†	54.3±42.2^*,†	33.9±23.9	33.9±23.9	27.4±27.3
HOMA-IR	1.7±1.9^*,†	1.3±1.3	0.9±0.8	0.9±0.8	0.8±1.0
IFG/IGT (%)	11.0	11.5	4.4	3.1	4.3
DM (%)	5.2	1.2	0	0.2	0
MetS (%)	20.8	14.0	2.9	2.2	2.4
*P<0.05 vs controls; ^†P<0.05 vs OM+PCO; ^‡P<0.05 vs HA+PCO; ^§P<0.05 vs OM+HA.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Endocrine Abstracts

P932